MX2018009341A - Formulaciones tamponadas para una mayor estabilidad de anticuerpos. - Google Patents
Formulaciones tamponadas para una mayor estabilidad de anticuerpos.Info
- Publication number
- MX2018009341A MX2018009341A MX2018009341A MX2018009341A MX2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A MX 2018009341 A MX2018009341 A MX 2018009341A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- antibody stability
- enhanced antibody
- buffer formulations
- salt
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229960002964 adalimumab Drugs 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 159000000021 acetate salts Chemical class 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001483 arginine derivatives Chemical class 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 150000002411 histidines Chemical class 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290654P | 2016-02-03 | 2016-02-03 | |
| PCT/US2017/016040 WO2017136433A1 (en) | 2016-02-03 | 2017-02-01 | Buffer formulations for enhanced antibody stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009341A true MX2018009341A (es) | 2019-05-15 |
Family
ID=58046768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009341A MX2018009341A (es) | 2016-02-03 | 2017-02-01 | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11285210B2 (enExample) |
| EP (1) | EP3411401A1 (enExample) |
| JP (1) | JP7084308B2 (enExample) |
| CN (1) | CN109563161A (enExample) |
| AU (1) | AU2017213775A1 (enExample) |
| CA (1) | CA3013336A1 (enExample) |
| MX (1) | MX2018009341A (enExample) |
| WO (1) | WO2017136433A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106170298B (zh) | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | 用于提高抗体稳定性的缓冲液制剂 |
| ES2572919T3 (es) * | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246271A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| KR20210102954A (ko) * | 2019-01-11 | 2021-08-20 | 삼성바이오에피스 주식회사 | 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 |
| KR20220064998A (ko) * | 2019-09-19 | 2022-05-19 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 콜레스테롤 관련 질환을 예방하거나 치료하기 위한 방법에 있어서 항 pcsk9 항체의 용도 |
| IL297986A (en) | 2020-05-08 | 2023-01-01 | Genmab As | Bispecific antibodies against cd3 and cd20 |
| WO2022135395A1 (zh) * | 2020-12-22 | 2022-06-30 | 百奥泰生物制药股份有限公司 | 稳定的抗体制剂及其制备方法和应用 |
| GB202115121D0 (en) * | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115127D0 (en) * | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992013876A1 (en) | 1991-02-01 | 1992-08-20 | Coulter Corporation | METHOD OF PRODUCING F(ab')2 FRAGMENTS OF IMMUNOGLOBULINS |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CN103275221B (zh) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
| DK1308456T3 (da) | 1998-05-06 | 2007-12-27 | Genentech Inc | Antistofoprensning ved ionbytterkromatografi |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| MY151032A (en) | 2002-07-19 | 2014-03-31 | Abbott Lab S A | Treatment of tnf? related disorders |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| US8227241B2 (en) | 2004-03-12 | 2012-07-24 | Unigene Laboratories, Inc. | Bacterial host cell for the direct expression of peptides |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| HUE028410T2 (en) | 2005-03-08 | 2016-12-28 | Pfizer Prod Inc | Anti-ctla-4 antibody compositions |
| CA2608728A1 (en) | 2005-05-16 | 2006-11-23 | Abbott Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
| CA2608579C (en) | 2005-05-26 | 2019-09-10 | Cytos Biotechnology Ag | Scalable fermentation process |
| EP2390267B1 (en) | 2005-06-07 | 2013-06-05 | ESBATech - a Novartis Company LLC | Stable and soluble antibodies inhibiting TNF(alpha) |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR058140A1 (es) | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| NZ567286A (en) | 2005-11-01 | 2012-03-30 | Abbott Biotechnolgy Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| KR20150064254A (ko) | 2006-04-05 | 2015-06-10 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
| EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| EP2703010A3 (en) | 2006-04-10 | 2014-08-06 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of rheumatoid arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| SG173339A1 (en) | 2006-06-30 | 2011-08-29 | Abbott Biotech Ltd | Automatic injection device |
| JP5437633B2 (ja) | 2006-09-11 | 2014-03-12 | 株式会社 免疫生物研究所 | モノクローナル抗体およびその用途 |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2500415A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| MX345141B (es) | 2006-09-13 | 2017-01-18 | Abbvie Inc * | Mejoras de cultivos celulares. |
| NZ576133A (en) | 2006-10-27 | 2012-10-26 | Abbott Biotech Ltd | Crystalline anti-htnfalpha antibodies |
| BRPI0809361A2 (pt) | 2007-03-30 | 2014-09-02 | Abbott Lab | Elementos de vetor de expressão recombinante (reves) para melhorar a expressão de proteínas recombinantes em células hospedeiras |
| ES2624185T3 (es) | 2007-04-26 | 2017-07-13 | Chugai Seiyaku Kabushiki Kaisha | Método de cultivo celular que utiliza un medio enriquecido con aminoácidos |
| WO2008150491A2 (en) | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US8753839B2 (en) | 2007-08-08 | 2014-06-17 | Abbvie Inc. | Compositions and methods for crystallizing antibodies |
| CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| SG186607A1 (en) | 2007-11-30 | 2013-01-30 | Abbott Lab | Protein formulations and methods of making same |
| WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| ES2579231T3 (es) | 2008-01-15 | 2016-08-08 | Abbvie Inc | Vectores de expresión de mamíferos mejorados y usos de los mismos |
| JP6078217B2 (ja) | 2008-01-15 | 2017-02-08 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 粉末化されたタンパク質組成物及びその作製方法 |
| EP2081025B1 (en) | 2008-01-15 | 2010-03-10 | Universiteit Utrecht Holding B.V. | Method for determining the amino acid sequence of peptides |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| WO2009118662A2 (en) | 2008-03-24 | 2009-10-01 | Abbott Biotechnology Ltd. | Methods and compositions for treating bone loss |
| EP2282773B2 (en) | 2008-05-02 | 2025-03-05 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| TW201024319A (en) | 2008-10-20 | 2010-07-01 | Abbott Lab | Antibodies that bind to IL-12 and methods of purifying the same |
| NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| EP2346897A2 (en) | 2008-10-20 | 2011-07-27 | Abbott Laboratories | Viral inactivation during purification of antibodies |
| BRPI0919979A2 (pt) | 2008-10-29 | 2015-12-15 | Wyeth Llc | formulações de moléculas de ligação de antígeno de domínio único |
| WO2010062896A1 (en) | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| US20120053080A1 (en) | 2009-03-09 | 2012-03-01 | Juan Cui | Protein markers identification for gastric cancer diagnosis |
| SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| JP5744856B2 (ja) | 2009-06-02 | 2015-07-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | フコシル化欠損細胞 |
| AU2010256455A1 (en) | 2009-06-05 | 2012-01-19 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| WO2011028962A1 (en) | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody coformulations |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| JP6039550B2 (ja) | 2010-05-18 | 2016-12-07 | アッヴィ・インコーポレイテッド | タンパク質の精製装置および方法 |
| PL3299380T3 (pl) | 2010-05-25 | 2024-12-16 | F. Hoffmann-La Roche Ag | Sposoby oczyszczania polipeptydów |
| PL2575884T3 (pl) | 2010-06-03 | 2018-12-31 | Abbvie Biotechnology Ltd | Zastosowania i kompozycje do leczenia ropni mnogich pach (HS) |
| KR20130114143A (ko) | 2010-09-20 | 2013-10-16 | 애브비 인코포레이티드 | 모사 이동층 크로마토그래피를 이용한 항체의 정제 |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| WO2012051147A1 (en) | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| EP2660328A4 (en) | 2010-12-28 | 2016-07-13 | Chugai Pharmaceutical Co Ltd | ANIMAL CELL CULTURE METHOD |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| DK2726600T3 (en) | 2011-07-01 | 2017-05-15 | Amgen Inc | Mammalian Cell Culture |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| EP2764082B1 (en) | 2011-10-04 | 2018-05-23 | Expression Pathology, Inc. | Srm/mrm assay for the ephrin type-a receptor 2 protein |
| AU2012328921B2 (en) | 2011-10-24 | 2017-05-11 | Abbvie Inc. | Immunobinders directed against TNF |
| US20140288278A1 (en) | 2011-10-31 | 2014-09-25 | Joseph Nti-Gyabaah | Chromatography process for resolving heterogeneous antibody aggregates |
| WO2013114165A1 (en) | 2012-01-30 | 2013-08-08 | Dr Reddy's Laboratories Limited | Process of obtaining glycoprotein composition with increased afucosylation content |
| WO2013114164A1 (en) | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| EP2863951A1 (en) | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| KR102238677B1 (ko) | 2012-09-07 | 2021-04-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
| JP5874587B2 (ja) | 2012-09-10 | 2016-03-02 | 株式会社島津製作所 | アミノ酸配列解析方法及び装置 |
| NO2760138T3 (enExample) | 2012-10-01 | 2018-08-04 | ||
| CN104822826B (zh) | 2012-10-15 | 2019-04-30 | 百时美施贵宝公司 | 用于蛋白产生的哺乳动物细胞培养过程 |
| WO2014099636A1 (en) | 2012-12-18 | 2014-06-26 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-tnf alpha antibody |
| US9452138B2 (en) | 2012-12-28 | 2016-09-27 | Abbott Cardiovascular Systems Inc. | Delivery of biologic therapeutics |
| AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US20140271633A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Mammalian cell culture performance through surfactant supplementation of feed media |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| AU2013384204B2 (en) | 2013-03-14 | 2017-03-16 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
| EP2990485B1 (en) | 2013-04-25 | 2019-09-11 | Kaneka Corporation | Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody |
| WO2014182658A1 (en) | 2013-05-06 | 2014-11-13 | Abbvie Inc. | Compositions for cell culture and methods of using the same |
| TWI596107B (zh) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
| WO2015051310A2 (en) | 2013-10-03 | 2015-04-09 | Bioanalytix, Inc. | Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic |
| CN106170298B (zh) | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | 用于提高抗体稳定性的缓冲液制剂 |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015140700A1 (en) | 2014-03-19 | 2015-09-24 | Dr. Reddy's Laboratories Limited | Cell culture process |
| EP3050557A1 (en) * | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| HUP1400510A1 (hu) | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| CN105044222B (zh) | 2014-12-19 | 2017-09-12 | 浙江辉肽生命健康科技有限公司 | 生物活性多肽的分析测试和鉴定方法 |
| WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AR103544A1 (es) | 2015-01-28 | 2017-05-17 | Mabxience S A | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a |
| CN105779394B (zh) | 2015-03-20 | 2020-03-24 | 广东东阳光药业有限公司 | 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法 |
| WO2017120359A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition |
| WO2017120347A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Modulation of afucosylated species in a monoclonal antibody composition |
| CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| AU2017214586A1 (en) | 2016-02-04 | 2018-08-16 | Outlook Therapeutics, Inc. | Methods for identifying and analyzing amino acid sequences of proteins |
-
2017
- 2017-02-01 CN CN201780019727.6A patent/CN109563161A/zh active Pending
- 2017-02-01 US US16/072,991 patent/US11285210B2/en active Active
- 2017-02-01 WO PCT/US2017/016040 patent/WO2017136433A1/en not_active Ceased
- 2017-02-01 JP JP2018540113A patent/JP7084308B2/ja active Active
- 2017-02-01 CA CA3013336A patent/CA3013336A1/en active Pending
- 2017-02-01 MX MX2018009341A patent/MX2018009341A/es unknown
- 2017-02-01 EP EP17705527.4A patent/EP3411401A1/en not_active Withdrawn
- 2017-02-01 AU AU2017213775A patent/AU2017213775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7084308B2 (ja) | 2022-06-14 |
| JP2019504086A (ja) | 2019-02-14 |
| WO2017136433A1 (en) | 2017-08-10 |
| EP3411401A1 (en) | 2018-12-12 |
| CA3013336A1 (en) | 2017-08-10 |
| US11285210B2 (en) | 2022-03-29 |
| AU2017213775A1 (en) | 2018-08-16 |
| CN109563161A (zh) | 2019-04-02 |
| US20190030163A1 (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009341A (es) | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| IL280467A (en) | Antibody constructs for cldn18.2 and cd3 | |
| IL287025A (en) | Systems and methods to classify antibodies | |
| MX374124B (es) | Formulaciones de tampón para la estabilidad de anticuerpo mejorada. | |
| HRP20210924T1 (hr) | Agonist glukokortikoidnog receptora i njegovi imunokonjugati | |
| MA53905A (fr) | Anticorps stabilisant trem2 | |
| EP3784699A4 (en) | OPTIMIZED ANTI-TL1A ANTIBODIES | |
| MY191169A (en) | Anti-fcrh5 antibodies | |
| MA52212A (fr) | Anticorps multivalent | |
| MA71409A (fr) | Constructions d'anticorps pour dll3 et cd3 | |
| MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MX2019009660A (es) | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. | |
| BR112016025291A2 (pt) | conjugados de anticorpo anti-ptk7-fármaco | |
| UY40974A (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos | |
| JO3772B1 (ar) | صيغة جسم مضاد لـ cgrp | |
| MX385853B (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| PL3576788T3 (pl) | Kompozycja farmaceutyczna o niskim ph zawierająca konstrukty przeciwciał angażujących komórki t | |
| MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
| EP4070818A3 (en) | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy | |
| IL262266A (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| WO2018075692A3 (en) | Antibody constructs | |
| MX2012013268A (es) | Formulaciones de anticuerpos de alta concentracion. | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| MA53831A (fr) | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques |